Connexion
E-mail
Mot de passe
Afficher le mot de passe
Retenir
Mot de passe oublié ?
Devenir membre gratuitement
Inscription
Inscription
Devenir membre
Inscription gratuite
Devenir client
Découvrez nos services
Paramètres
Paramètres
Cotations dynamiques 
OFFON

NOVOCURE LIMITED

(NVCR)
  Rapport
SynthèseCotationsGraphiquesActualitésNotationsAgendaSociétéFinancesConsensusRévisionsDérivésFondsCommunauté 
SynthèseToute l'actualitéReco analystesAutres languesCommuniquésPublications officiellesActualités du secteurAnalyses Zonebourse
Actualités dans d'autres langues sur NOVOCURE LIMITED
20/01Health Care Stocks Higher Ahead of Thursday's Close
20/01Health Care Stocks Posting Gains This Afternoon
10/01NovoCure Reports Preliminary Q4 Net Revenue of $133.2 Million
10/01NOVOCURE : DMC interim analysis for INNOVATE-3 pivotal trial in ovarian cancer anticipated..
10/01Novocure Announces Preliminary Full Year and Fourth Quarter 2021 Net Revenues and Provi..
10/01NovoCure Limited Reports Preliminary, Unaudited Revenue Results for the Fourth Quarter ..
05/01INSIDER SELL : NovoCure
04/01Novocure to Participate in the 40th Annual J.P. Morgan Healthcare Conference
2021NOVOCURE LTD : Other Events (form 8-K)
2021NOVOCURE LIMITED(NASDAQGS : NVCR) added to NASDAQ Biotechnology Index
2021NOVOCURE : Signs Agreement to Acquire and Construct Building in Downtown Portsmouth, New H..
2021Novocure Signs Agreement to Acquire and Construct Building in Downtown Portsmouth, New ..
2021NOVOCURE LTD : Entry into a Material Definitive Agreement, Other Events, Financial Stateme..
2021Novocure Announces 4th Annual AACR-Novocure Grants for Tumor Treating Fields Research P..
2021INSIDER BUY : NovoCure
2021Novocure to Participate in Two Upcoming Investor Conferences
2021NovoCure Completes Patient Enrollment in Phase 3 Trial of Tumor Treating Fields in Non..
2021Novocure Announces Last Patient Enrolled in Phase 3 Pivotal LUNAR Trial of Tumor Treati..
2021NovoCure Limited Announces Last Patient Enrolled in Phase 3 Pivotal LUNAR Trial of Tumo..
2021Novocure Announces 31 Presentations on Tumor Treating Fields at Society for Neuro-Oncol..
20212-THE-TOP Phase 2 Trial Reports Positive Top-Line Results in Newly Diagnosed Glioblasto..
2021Novocure Announces 2-THE-TOP Phase 2 Trial Reports Positive Top-Line Results in Newly D..
2021NOVOCURE : Q3 Earnings Snapshot
2021NovoCure Swings to Net Loss in Q3 Despite Higher Revenue
2021NOVOCURE LTD Management's Discussion and Analysis of Financial Condition and Results o..
2021Novocure Reports Third Quarter 2021 Financial Results and Provides Company Update - For..
2021NovoCure Limited Reports Earnings Results for the Third Quarter and Nine Months Ended S..
2021Earnings Flash (NVCR) NOVOCURE Posts Q3 Revenue $133.6M, vs. Street Est of $141.2M
2021Earnings Flash (NVCR) NOVOCURE Posts Q3 Loss $-0.13, vs. Street Est of $-0.06
2021Novocure Reports Third Quarter 2021 Financial Results and Provides Company Update
2021Novocure Announces Last Patient Enrolled in Phase 3 Pivotal INNOVATE-3 Trial of Tumor T..
2021Novocure Announces Last Patient Enrolled in Phase 3 Pivotal INNOVATE-3 Trial of Tumor T..
2021NOVOCURE : Announces 15 Presentations at the American Society for Radiation Oncology 2021 ..
2021ZAI LAB : Novocure in Phase 2 Trial of Gastric Cancer Combo Therapy in Greater China
2021NOVOCURE : to Report Third Quarter 2021 Financial Results
2021NOVOCURE : and Zai Lab Announce Last Patient Enrolled in Phase 2 Pilot Trial of Tumor Trea..
2021NOVOCURE : Zai Lab and Novocure Announce Last Patient Enrolled in Phase 2 Pilot Trial of T..
2021Novocure and Zai Lab Announce Last Patient Enrolled in Phase 2 Pilot Trial of Tumor Tre..
2021NOVOCURE : und Roche kooperieren bei klinischen Studien, um Tumortherapiefelder als Teil e..
2021NOVOCURE : Roche To Co-Develop Tumor Treating Fields For Pancreatic Cancer
2021NOVOCURE : Roche Team Up to Develop Tumor Treating Fields for Potential Treatment of Pancr..
2021NOVOCURE : Announces Clinical Trial Collaboration with Roche to Evaluate Tumor Treating Fi..
2021NOVOCURE : Gets FDA Breakthrough Device Designation for Tumor Treating Fields in Liver Can..
2021NOVOCURE : FDA Grants Breakthrough Device Designation to the NovoTTF-200T™ System fo..
2021FDA Grants Breakthrough Device Designation to the NovoTTF-200T™ System for Advanced Liv..
2021INSIDER SELL : Novocure
2021NOVOCURE : to Participate in the 2021 Wells Fargo Virtual Healthcare Conference
2021NOVOCURE : Appoints Bill Burke as Chief Human Resources Officer
2021Novocure Appoints Bill Burke as Chief Human Resources Officer
2021INSIDER TRENDS : NovoCure Insider Extends 90-Day Selling Trend
2021INSIDER TRENDS : NovoCure Insider Extends 90-Day Selling Trend
2021INSIDER TRENDS : Insider Prolongs Selling Trend at NovoCure
2021INSIDER TRENDS : Insider Prolongs 90-Day Selling Trend at NovoCure
2021NOVOCURE : Swings To Q2 Net Loss, Reports Higher Revenue; Shares Decline Premarket
2021NOVOCURE : Q2 Earnings Snapshot
2021NOVOCURE : Management's Discussion and Analysis of Financial Condition and Results of Oper..
2021NOVOCURE : Earnings Flash (NVCR) NOVOCURE Reports Q2 Revenue $133.5M, vs. Street Est of $1..
2021NOVOCURE : Earnings Flash (NVCR) NOVOCURE Posts Q2 Loss $-0.14, vs. Street Est of $0.01
2021NOVOCURE : Reports Second Quarter 2021 Financial Results and Provides Company Update
2021Novocure Limited Reports Earnings Results for the Second Quarter Ended June 30, 2021
2021NOVOCURE : Announces Recipients of 3rd Annual AACR-Novocure : Grants for Tumor Treating Fi..
2021NOVOCURE : to Report Second Quarter 2021 Financial Results
2021S&P 500 Hits Fresh Record High as Initial Jobless Claims Fall
2021CLOSE UPDATE : S&P 500 Hits Fresh Record High as Initial Jobless Claims Fall
2021Equities Mixed Midday With Techs Lower, Yields Gaining After Jobless Claims Dive to 15-..
2021MIDDAY REPORT : US Stocks Mixed With Techs Lower, Yields Advancing After Jobless Claims Di..
2021SECTOR UPDATE : Health Care Stocks Steady Premarket Thursday
2021NOVOCURE : Reports Final Result From Liver Cancer Study of Sorafenib With TTFields; Shares..
2021NOVOCURE : Presents Final Safety and Efficacy Results from its Phase 2 Pilot HEPANOVA Tria..
2021Novocure Presents Final Safety and Efficacy Results from Its Phase 2 Pilot HEPANOVA Tri..
2021NOVOCURE LIMITED(NASDAQGS : NVCR) dropped from Russell 2500 Growth Index
2021NOVOCURE LIMITED(NASDAQGS : NVCR) dropped from Russell 2500 Index
2021NOVOCURE : Launches Study in Europe to Test Use of Flexible Torso Array
2021NOVOCURE : Initiates Usability Study for Flexible Torso Array
2021NovoCure Limited Initiates Usability Study for Flexible Torso Array
1  2  3  4  5  6  7Suiv.
Prochain événement sur NOVOCURE LIMITED